title: Treatment with human analog (GlyA21, ArgB31, ArgB32) insulin glargine (HOE901) resolves a generalized allergy to human insulin in type 1 diabetes.
authors.forename: H
authors.initials: H
authors.lastname: Moriyama
authors.forename: M
authors.initials: M
authors.lastname: Nagata
authors.forename: K
authors.initials: K
authors.lastname: Fujihira
authors.forename: K
authors.initials: K
authors.lastname: Yamada
authors.forename: S A
authors.initials: SA
authors.lastname: Chowdhury
authors.forename: S
authors.initials: S
authors.lastname: Chakrabarty
authors.forename: Z
authors.initials: Z
authors.lastname: Jin
authors.forename: H
authors.initials: H
authors.lastname: Yasuda
authors.forename: H
authors.initials: H
authors.lastname: Ueda
authors.forename: K
authors.initials: K
authors.lastname: Yokono
mesh_terms: D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D004342:Drug Hypersensitivity; D006801:Humans; D007328:Insulin / Q000031:analogs & derivatives* / Q000276:immunology* / Q000627:therapeutic use*; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D008297:Male; D008875:Middle Aged
chemical_list: D007328:Insulin; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine